Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients

Cortex

Volumn 60, Issue , 2014, Pages 3-9

  Frisaldi, Elisa ^a,b   Carlino, Elisa ^a,b   Lanotte, Michele ^a   Lopiano, Leonardo ^a   Benedetti, Fabrizio ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b National Institute of Neuroscience   (Italy)

Author keywords

Basal ganglia; Parkinson; Placebo response; Single neuron recording

Indexed keywords

BEHAVIOR; BRAIN DEPTH STIMULATION; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; EMOTION; EVOKED MUSCLE RESPONSE; GLOBUS PALLIDUS; HUMAN; MOTOR PERFORMANCE; NEUROIMAGING; PARKINSON DISEASE; PLACEBO EFFECT; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; SUBTHALAMUS; THALAMUS; THALAMUS NUCLEUS; NERVE CELL; NERVE TRACT; PATHOPHYSIOLOGY; PHYSIOLOGY;

DEEP BRAIN STIMULATION; HUMANS; NEURAL PATHWAYS; NEURONS; PARKINSON DISEASE; PLACEBO EFFECT; SUBTHALAMIC NUCLEUS; THALAMUS;

EID: 84910071545     PISSN: 00109452     EISSN: 19738102     Source Type: Journal    
DOI: 10.1016/j.cortex.2013.12.003     Document Type: Review

References (54)

1. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience 1986, 9:357-381.
2. Benedetti F. Placebo effects. Understanding the mechanisms in health and disease 2008, Oxford University Press, Oxford.
3. Benedetti F., Amanzio M., Rosato R., Blanchard C. Non-opioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nature Medicine 2011, 17:1228-1230.
4. Benedetti F., Amanzio M., Vighetti S., Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. Journal of Neuroscience 2006, 26:12014-12022.
5. Benedetti F., Carlino E., Pollo A. How placebos change the patient's brain. Neuropsychopharmacology 2011, 36:339-354.
6. Benedetti F., Colloca L., Torre E., Lanotte M., Melcarne A., Pesare M., et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nature Neuroscience 2004, 7:587-588.
7. Benedetti F., Lanotte M., Colloca L., Ducati A., Zibetti M., Lopiano L. Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. Journal of Physiology 2009, 587:3869-3883.
8. Benedetti F., Pollo A., Lopiano L., Lanotte M., Vighetti S., Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. Journal of Neuroscience 2003, 23:4315-4323.
9. Bergman H., Wichmann T., Karmon B., DeLong M.R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. Journal of Neurophysiology 1994, 72:507-520.
10. Blandini F., Nappi G., Tassorelli C., Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Progress in Neurobiology 2000, 62:63-88.
11. Brody H. The placebo response 2000, Harper Collins, New York.
12. Colloca L., Benedetti F. Placebos and painkillers: is mind as real as matter?. Nature Reviews Neuroscience 2005, 6:545-552.
13. Diederich N.J., Goetz C.G. The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 2008, 71:677-684.
14. de la Fuente-Fernández R., Phillips A.G., Zamburlini M., Sossi V., Calne D.B., Ruth T.J., et al. Dopamine release in human ventral striatum and expectation of reward. Behavioural Brain Research 2002, 136:359-363.
15. de la Fuente-Fernández R., Ruth T.J., Sossi V., Schulzer M., Calne D.B., Stoessl A.J. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001, 293:1164-1166.
16. de la Fuente-Fernández R., Schulzer M., Stoessl A.J. The placebo effect in neurological disorders. Lancet Neurology 2002, 1:85-91.
17. Galpern W.R., Corrigan-Curay J., Lang A.E., Kahn J., Tagle D., Barker R.A., et al. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurology 2012, 11:643-650.
18. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Medicine 2003, 9:589-595.
19. Goetz C.G., Laska E., Hicking C., Damier P., Müller T., Nutt J., et al. Placebo influences on dyskinesia in Parkinson's disease. Movement Disorders 2008, 23:700-707.
20. Goetz C.G., Leurgans S., Raman R. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Movement Disorders 2002, 17:283-288.
21. Goetz C.G., Leurgans S., Raman R., Stebbins G.T. Objective changes in motor function during placebo treatment in PD. Neurology 2000, 54:710-714.
22. Goetz C.G., Wuu J., McDermott M.P., Adler C.H., Fahn S., Freed C.R., et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Movement Disorders 2008, 23:690-699.
23. Gross R.E., Watts R.L., Hauser R.A., Bakay R.A., Reichmann H., Von Kummer R., et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology 2011, 10:509-519.
24. Haber S.N. The primate basal ganglia: parallel and integrative networks. Journal of Chemical Neuroanatomy 2003, 26:317-330.
25. Hutchison W.D., Allan R.J., Opitz H., Levy R., Dostrovsky J.O., Lang A.E., et al. Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Annals of Neurology 1998, 44:622-628.
26. Ikemoto S., Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Research Reviews 1999, 31:6-41.
27. Keitel A., Wojtecki L., Hirschmann J., Hartmann C.J., Ferrea S., Südmeyer M., et al. Motor and cognitive placebo-/nocebo-responses in Parkinson's disease patients with deep brain stimulation. Behavioural Brain Research 2013, 250:199-205.
28. Knutson B., Cooper J.C. Functional magnetic resonance imaging of reward prediction. Current Opinion in Neurology 2005, 18:411-417.
29. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology 2006, 59:459-466.
30. Levy R., Dostrovskym J.O., Lang A.E., Sime E., Hutchison W.D., Lozano A.M. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. Journal of Neurophysiology 2001, 86:249-260.
31. Lidstone S.C., Schulzer M., Dinelle K., Mak E., Sossi V., Ruth T.J., et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Archives of General Psychiatry 2010, 67:857-865.
32. Limousin P., Greene J., Pollak P., Rothwell J., Benabid A.L., Frackowiak R. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Annals of Neurology 1997, 42:283-291.
33. Lou J.S., Dimitrova D.M., Hammerschlag R., Nutt J., Hunt E.A., Eaton R.W., et al. Effect of expectancy and personality on cortical excitability in Parkinson's disease. Movement Disorders 2013, 28(9):1257-1262. 10.1002/mds.25471.
34. Lozano A.M., Lang A.E., Levy R., Hutchison W., Dostrovsky J. Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Annals of Neurology 2000, 47(Suppl. 1):S141-S146.
35. Marks W.J., Bartus R.T., Siffert J., Davis C.S., Lozano A., Boulis N., et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology 2010, 9:1164-1172.
36. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurology 2008, 7:400-408.
37. McRae C., Cherin E., Yamazaki T.G., Diem G., Vo A.H., Russell D., et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Archives of General Psychiatry 2004, 61:412-420.
38. Mercado R., Constantoyannis C., Mandat T., Kumar A., Schulzer M., Stoessl A.J., et al. Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Movement Disorders 2006, 21:1457-1461.
39. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology 2003, 54:403-414.
40. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Research Reviews 1995, 20:128-154.
41. Péron J., Frühholz S., Vérin M., Grandjean D. Subthalamic nucleus: a key structure for emotional component synchronization in humans. Neuroscience & Biobehavioral Reviews 2013, 37:358-373.
42. Petrovic P., Dietrich T., Fransson P., Andersson J., Carlsson K. Placebo in emotional processing - induced expectations of anxiety relief activate a generalized modulatory network. Neuron 2005, 46:957-969.
43. Pollo A., Torre E., Lopiano L., Rizzone M., Lanotte M., Cavanna A., et al. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. NeuroReport 2002, 13:1383-1386.
44. Scherer K.R., Schorr A., Johnstone T. Appraisal processes in emotion: Theory, methods, research 2001, Oxford University Press, New York.
45. Schultz W. Getting formal with dopamine and reward. Neuron 2002, 36:241-263.
46. Schultz W., Tremblay L., Hollerman J.R. Reward processing in primate orbitofrontal cortex and basal ganglia. Cerebral Cortex 2000, 10:272-284.
47. Scott D.J., Stohler C.S., Egnatuk C.M., Wang H., Koeppe R.A., Zubieta J.-K. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 2007, 55:325-336.
48. Shetty N., Friedman J.H., Kieburtz K., Marshall F.J., Oakes D. The placebo response in Parkinson's disease. Parkinson Study Group. Clinical Neuropharmacology 1999, 22:207-212.
49. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. Journal of Neurosurgery 2005, 102:216-222.
50. Stefani A., Bassi A., Mazzone P., Pierantozzi M., Gattoni G., Altibrandi M.G., et al. Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the "indirect pathway". Clinical Neurophysiology 2002, 113:91-100.
51. Stover N.P., Bakay R.A.E., Subramanian T., Raiser C.D., Cornfeldt M.L., Schweikert A.W., et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Archives of Neurology 2005, 62:1833-1837.
52. Strafella A.P., Ko J.H., Monchi O. Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation. NeuroImage 2006, 31:1666-1672.
53. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nature Medicine 2010, 16:1277-1283.
54. Vase L., Robinson M.E., Verne G.N., Price D.D. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005, 115:338-347.